PHASiFY Health Announces $34 Million Series A Funding to Advance Urine-Based Liquid Biopsy for Early Disease Detection

Phase Scientific International Limited (hereinafter referred to as “Phase Scientific”) announced today the successful completion of a $34 million Series A financing round. Phase Scientific is an innovative biotechnology company whose breakthrough urine-based genetic testing technology has brought about a transformative change in early disease detection. This funding round represents the largest Series A financing in the Asian diagnostics sector since 2019, fully reflecting investors’ confidence in Phase Scientific’s PHASIFY™ technology and growth strategy. The round was led by a private equity fund under Value Partners Group (Stock Code: 806.HK), one of Asia’s largest independent asset management firms, and saw active participation from several new investors focused on healthcare and life sciences, with continued follow-on support from existing global investors.

PHASE Scientific is a pioneer in urine-based liquid biopsy diagnostic technologies. Its proprietary PHASIFY™ urine concentration technology enhances the capture sensitivity of biomarkers for detection to more than ten times the industry’s gold standard. Building on this patented technology, the company is developing a series of non-invasive diagnostic solutions spanning early cancer screening, women’s health, and infectious diseases. The PHASIFY™ technology breaks through the limitations of traditional invasive screening methods, facilitating at-home sample collection and empowering individuals to engage in self-managed health care and preventive wellness.

PHASE Scientific has successfully launched and commercialized over 30 innovative diagnostic products, with its business spanning multiple fields including respiratory health, gastrointestinal health, women’s health, sexual health, pediatric health, and oncology. To date, the company has provided more than 100 million test kits in over 30 countries worldwide and completed more than 8 million laboratory tests. Leveraging years of excellent operational and business performance, PHASE Scientific developed the world’s first human papillomavirus (HPV) urine-based test. This significant technological breakthrough has been clinically validated and internationally recognized. In the latest clinical study conducted in collaboration with Shenzhen Hospital of Peking University, this urine test demonstrated a sensitivity of 93.4% for CIN2+ lesions (including cervical precancerous lesions and cervical cancer). Furthermore, for the detection of HPV types 16 and 18, it achieved a high concordance rate of over 97% with the gold-standard clinician-collected sample test (Roche Cobas 4800). This innovative technology was honored with the “Outstanding Clinical Research Award” at the 2025 Annual Meeting of the American Society for Colposcopy and Cervical Pathology (ASCCP) and was featured at the conference of the Chinese Society of Colposcopy and Cervical Pathology (CSCCP) under the China Association for Birth Science and Health, fully demonstrating its growing international influence and recognition. These achievements further prove that PHASiFY™ technology not only improves the convenience and comfort of cervical cancer screening but also significantly enhances testing accuracy.

Dr. Zhao Yantao, Chairman and Chief Executive Officer of PHASE Scientific, stated, “This Series A financing round represents a milestone for us, not only validating the transformative potential of PHASE’s technology but also reflecting the urgent global demand for precision and accessibility in early disease detection. The funds raised will be used to accelerate the launch of next-generation urine-based diagnostic products, fulfilling our mission to make innovative technologies universally accessible for better health.”

Dr. Leung Chuen Hing, Partner for Healthcare Investments at Value Partners Group, stated: “We are delighted to partner with Phase Scientific and witness its rapid development in the field of early disease screening, as well as the innovative solutions it provides to address public health challenges. This groundbreaking technology has brought about significant transformation by delivering unique, patient-centric solutions while ensuring clinical precision, thereby advancing the field of early disease detection. Phase Scientific boasts an excellent management team, a clear development strategy, industry-leading technological capabilities, and innovative solutions that combine social value with commercial potential, all of which align closely with our investment strategy.”

Phase Scientific was established in 2015, with its headquarters located in the Hong Kong Special Administrative Region of China. The company has established a global presence in Southern California, USA, and the Greater Bay Area of China, positioning itself in key hubs of global medical innovation to fully leverage local resource advantages in support of its R&D and commercialization efforts.

Dr. Zhao stated, “As a Hong Kong-born scientist and entrepreneur, I am immensely proud that our PHASIFY™ technology, developed in Hong Kong, has gained global recognition. Our journey clearly demonstrates that Hong Kong possesses the strength to drive breakthrough developments in biotechnology and address global healthcare challenges, leveraging its exceptional talent pool, advanced infrastructure, and innovation-driven ecosystem. This is merely the beginning of our journey. In response to growing healthcare demands, we remain committed to advancing our innovative technologies and leading the development of proactive health management and preventive medicine.”

(Editor’s Note: According to statistics from Precedence Research, the demand for non-invasive cancer diagnostics will drive the global liquid biopsy market to grow from USD 7.05 billion in 2025 to approximately USD 22.69 billion by 2034, at a compound annual growth rate (CAGR) of 13.91%.)）

PHASE Scientific is a rapidly growing biotechnology company dedicated to reshaping the new health ecosystem through innovative diagnostic and healthcare solutions. Headquartered in Hong Kong, China, with branches in the United States and the Greater Bay Area, the company is renowned for its independently developed proprietary technologies that enhance research and clinical diagnostic outcomes by efficiently and rapidly concentrating target analytes in samples. Since its inception, the company has received strong support from the Bill & Melinda Gates Foundation, the U.S. National Institutes of Health (NIH), the U.S. National Science Foundation (NSF), the Ministry of Science and Technology of China, the Innovation, Technology and Industry Bureau of the Hong Kong Special Administrative Region, and the Hong Kong Science and Technology Parks Corporation.

PHASIFY™ is the world’s first concentration technology specifically designed for molecular diagnostics. Its ability to extract target analytes from various liquid samples, particularly urine, surpasses the industry gold standard by more than 10-fold, setting a new benchmark for the field. This technology can process and concentrate large volumes of urine samples, significantly enhancing the sensitivity and accuracy of disease detection. This patented innovation has established PHASE Scientific as a pioneer in urine-based liquid biopsy diagnostics, with clinical validation achieved in the detection of HPV and multiple other cancers. By enabling convenient, non-invasive, and painless sample collection, PHASIFY™ opens up new possibilities for early disease screening, widespread diagnosis, and comprehensive testing.

Value Partners is a leading independent asset management company in Asia, dedicated to providing world-class investment services and products. Since its establishment in 1993, Value Partners has consistently adhered to value investing strategies in both Asian and global markets. In November 2007, Value Partners Group became the first asset management company to list on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 806.HK). Headquartered in Hong Kong, Value Partners Group maintains offices in Shanghai, Shenzhen, Singapore, and London. Its investment strategies span equities, fixed income, multi-asset, alternative investments, real estate, and quantitative investments, serving institutional and individual investors across the Asia-Pacific region, Europe, and the United States.